Artiva Biotherapeutics (ARTV) vs Fennec Pharmaceuticals (FENC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Artiva Biotherapeutics (ARTV) has outperformed Fennec Pharmaceuticals (FENC) over the past year, gaining 126.7% versus a gain of 14.8%. Fennec Pharmaceuticals is the larger company by market cap ($375.6 million vs $339.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARTV | FENC |
|---|---|---|
| Share price | $6.94 | $10.71 |
| Market cap | $339.30M | $375.57M |
| 1-day change | +2.06% | +0.75% |
| YTD return | +58.51% | +39.09% |
| 1-year return | +126.67% | +14.79% |
| 5-year return | — | +16.54% |
| Forward P/E | — | 11.30 |
| EPS (TTM) | $-3.23 | $-0.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.53 | $13.25 |
| 52-week low | $2.71 | $5.65 |
| Distance from 52-week high | -52.24% | -19.17% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +415.85% | +64.99% |
| Average volume | 402.95K | 193.45K |
| Shares outstanding | 48.89M | 35.07M |
| Employees | 115 | 35 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARTV has outperformed FENC by 111.9 percentage points over the past year.
About Artiva Biotherapeutics
ARTV stock →Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 115 employees
About Fennec Pharmaceuticals
FENC stock →Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees
ARTV vs FENC FAQ
Which is bigger, Artiva Biotherapeutics or Fennec Pharmaceuticals?
Fennec Pharmaceuticals (FENC) is larger, with a market capitalization of $375.57M compared with $339.30M for Artiva Biotherapeutics (ARTV).
Which stock has performed better over the past year, ARTV or FENC?
ARTV returned +126.67% over the past 12 months, compared with +14.79% for FENC (price return, excluding dividends). Past performance does not predict future results.
Are Artiva Biotherapeutics and Fennec Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.